These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 7409936)
1. Pharmacokinetics of prostaglandins: prediction of steady-state concentrations during intravenous infusion. Weiss M; Förster W Int J Clin Pharmacol Ther Toxicol; 1980; 18(8):344-7. PubMed ID: 7409936 [TBL] [Abstract][Full Text] [Related]
3. Minaxolone, a new steroidal anesthetic. Pharmacokinetics and organ extraction in sheep. Gourlay GK; Mather LE; Parkin KS Drug Metab Dispos; 1980; 8(6):452-5. PubMed ID: 6109615 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans. Angst MS; Dyck JB; Azarnoff DL; Goldblum R; Ho B; Gfroerer T; Linton EA; Glynn BP; Shafer SL Clin Pharmacol Ther; 1998 Nov; 64(5):499-510. PubMed ID: 9834042 [TBL] [Abstract][Full Text] [Related]
6. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer. Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403 [TBL] [Abstract][Full Text] [Related]
8. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Eppler SM; Combs DL; Henry TD; Lopez JJ; Ellis SG; Yi JH; Annex BH; McCluskey ER; Zioncheck TF Clin Pharmacol Ther; 2002 Jul; 72(1):20-32. PubMed ID: 12152001 [TBL] [Abstract][Full Text] [Related]
9. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Kharasch ED; Hoffer C; Walker A; Sheffels P Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566 [TBL] [Abstract][Full Text] [Related]
11. Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Britten CD; Baker SD; Denis LJ; Johnson T; Drengler R; Siu LL; Duchin K; Kuhn J; Rowinsky EK Clin Cancer Res; 2000 Sep; 6(9):3459-68. PubMed ID: 10999729 [TBL] [Abstract][Full Text] [Related]
12. Recirculatory pharmacokinetic model of the uptake, distribution, and bioavailability of prochlorperazine administered as a thermally generated aerosol in a single breath to dogs. Avram MJ; Henthorn TK; Spyker DA; Krejcie TC; Lloyd PM; Cassella JV; Rabinowitz JD Drug Metab Dispos; 2007 Feb; 35(2):262-7. PubMed ID: 17079359 [TBL] [Abstract][Full Text] [Related]
13. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044 [TBL] [Abstract][Full Text] [Related]
14. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794 [TBL] [Abstract][Full Text] [Related]
15. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. Imawaka H; Sugiyama Y J Pharmacol Exp Ther; 1998 Mar; 284(3):949-57. PubMed ID: 9495854 [TBL] [Abstract][Full Text] [Related]
16. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670 [TBL] [Abstract][Full Text] [Related]
17. Relationships between steady state blood concentrations and cardiac output during intravenous infusions. Upton RN Biopharm Drug Dispos; 2000 Mar; 21(2):69-76. PubMed ID: 11100908 [TBL] [Abstract][Full Text] [Related]
18. [Utilization of a mathematical model of the pharmacokinetics of streptomycin for maintaining its concentration in the blood at a given level under conditions of intravenous infusion]. Solov'ev VN; Firsov AA; Berezhinskaia VV; Fishman VM; Murav'eva SA Antibiotiki; 1974 Jun; 19(6):546-52. PubMed ID: 4850093 [No Abstract] [Full Text] [Related]
19. Apparent volume of distribution, pulmonary clearance and bioavailability of volatile or gaseous compounds after peripheral intravenous dosing. Chiou WL Res Commun Chem Pathol Pharmacol; 1974 Apr; 7(4):679-86. PubMed ID: 4828764 [No Abstract] [Full Text] [Related]
20. Prediction of steady state theophylline concentration during drug infusion. Johnson GF Iowa Med; 1984 Aug; 74(8):347-8, 350, 352. PubMed ID: 6490341 [No Abstract] [Full Text] [Related] [Next] [New Search]